Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
This report describes some experimental and clinical studies showing the following: (1) in animals under protection of mesna the dose of ifosfamide (Ifo) can be increased significantly; (2) fractionated administration of Ifo, cyclophosphamide (CPA), or the stabilized metabolite of cyclophosphamide (ASTA Z 7557) is less toxic than single push-injection of the same total daily dose and therapeutically more effective; and (3) in humans under the protection of mesna the continuous infusions of ifosfamide over 5 days leads to an increase of the MTD compared with single daily short-term infusion and responses in some solid tumors, e.g., soft tissue sarcomas.
D000818:Animals; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000633:toxicity; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000633:toxicity; D007263:Infusions, Parenteral; D007668:Kidney / Q000187:drug effects; D007928:Lethal Dose 50; D008297:Male; D015080:Mesna / Q000008:administration & dosage; D051379:Mice; D008815:Mice, Inbred Strains; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*
C037933:Asta Z 7557; D003520:Cyclophosphamide; D015080:Mesna; D007069:Ifosfamide